SOLIGENIX, INC.
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2016 Ended Jun 30, 2016 | Aug 12, 2016 | After market close | – | – | – |
| Q2 FY2013 Ended Jun 30, 2013 | Aug 21, 2013 | After market close | – | – | – |
| Q1 FY2013 Ended Mar 31, 2013 | May 8, 2013 | After market close | – | – | – |
| Q1 FY2012 Ended Mar 31, 2012 | May 15, 2012 | During market hours | – | – | – |
| Q2 FY2011 Ended Jun 30, 2011 | Aug 12, 2011 | During market hours | – | – | – |
| Q1 FY2011 Ended Mar 31, 2011 | May 13, 2011 | After market close | – | – | – |
| Q4 FY2010 Ended Dec 31, 2010 | Mar 29, 2011 | After market close | – | – | – |
| Q3 FY2010 Ended Sep 30, 2010 | Nov 16, 2010 | During market hours | – | – | – |
| Q2 FY2010 Ended Jun 30, 2010 | Aug 13, 2010 | Before market open | – | – | – |
| Q4 FY2009 Ended Dec 31, 2009 | Apr 1, 2010 | During market hours | – | – | – |
Press releases
Announcements Soligenix filed with the SEC
Soligenix Announces Interim Results from the Phase 3 FLASH 2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Other events · EX-99.1 to Form 8-K
Soligenix Details Recent Progress and Upcoming Milestones
Other events · EX-99.1 to Form 8-K
Soligenix Announces Pricing of $7.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Soligenix Announces Closing of $7.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
FDA Grants Soligenix Orphan Drug Designation for
Other events · EX-99.1 to Form 8-K
Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet’s Disease
Other events · EX-99.1 to Form 8-K
Soligenix Announces Reverse Stock Split
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Announces Pricing of $4.75 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™
Other events · EX-99.1 to Form 8-K
in this presentation, including statements regarding our future results of operations and financial position, business
Other events · EX-99.2 to Form 8-K
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Announces Pricing of $8.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Soligenix Announces Closing of $8.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Soligenix Provides Regulatory Update on HyBryte™
Other events · EX-99.1 to Form 8-K
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Other events · EX-99.1 to Form 8-K
Soligenix Announces Reverse Stock Split
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Series D Preferred Stock to Holders of its Common Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis
Other events · EX-99.1 to Form 8-K
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
Other events · EX-99.1 to Form 8-K
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses
Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Announces Formation of Psoriasis
Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K